Business
Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Yesafili® (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL is now publicly funded on the Ontario Drug Benefit Formulary/Comparative Drug Index for the advanced treatment of patients with retinal diseases in Canada. YESAFILI was the first biosimilar to EYLEA to b
About this update from Biocon Limited
[{"type":"text","content":"TORONTO, ON and BENGALURU, India, Sept. 18, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Yesafili® (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL is now publicly funded on the Ontario Drug Benefit Formulary/Comparative Drug Index for the advanced treatment of patients with retinal diseases in Canada. YESAFILI was the first biosimilar to EYLEA to be approved by Health Canada.","length":618,"tagName":"p"},{"type":"image","alt":"Biocon Biologics (PRNewsfoto/Biocon Biologics)","displaySize":"","headline":null,"caption":"Biocon Biologics (PRNewsfoto/Biocon Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/cnwgroup.com/f52c945188fde03caec2c4e41e57e558"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gWyWcCz7B.uyQ2.LsVkGvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/f52c945188fde03caec2c4e41e57e558","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2775049/biocon_biologics_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Ontario Drug Benefit (ODB) Formulary is the official listing that determines which prescription medicines are covered under the public insurance system in Ontario, Canada's largest province. This listing, which was effective August 29, 2025, ensures eligible patients will be covered through public funding, improving access to care.","length":346,"tagName":"p"},{"type":"text","content":"YESAFILI (aflibercept) is approved for treating neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular edema secondary to central or branch retinal vein occlusion (CRVO/BRVO), diabetic macular edema (DME) and myopic choroidal neovascularization (myopic CNV). Retinal conditions like wet AMD affect over 2 million Canadians1 and are a leading cause of irreversible vision loss worldwide, placing mounting pressure on patients, caregivers and healthcare systems.2","length":497,"tagName":"p"},{"type":"text","content":" Ramy Ayad, Head of Canada at Biocon Biologics, stated: "...